Support Alert

UPDATE: Class 4 Medicines Defect Information: Crescent Pharma Ltd, SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

The MHRA has been informed that further batches were released which did not contain the safety information, as detailed in the original class 4 notification. Please see details relating to the original batches and additional batches that are subject to this notification. The PIL link has also been updated.

Further information on the affected batches and advice for healthcare professionals can be found on the MHRA website.